Skip to main content


Common Name(s): Activated charcoal, Animal charcoal, Charcoal, Gas black, Lamp black, Oral charcoal adsorbent

Medically reviewed by Last updated on Jan 1, 2023.

Clinical Overview


Activated charcoal's main use is as an antidote in poisoning. It is promoted for use as an antiflatulent and in dyslipidemia, and has demonstrated benefit in wound healing, kidney disease, and diarrhea/gut dysbiosis. Activated charcoal is also commonly used in toothpastes and as a fine powder for brushing teeth. However, clinical studies to support these uses are lacking.

Activated charcoal's main use is as an antidote in poisoning; this is considered a medicinal use and should only be administered under medical supervision in an appropriate setting. The American Academy of Pediatrics does not recommend administration of activated charcoal in the home, especially in cases of acute poisoning in children.


Clinical studies are lacking to provide dosing information for activated charcoal.


The American Academy of Pediatrics does not recommend administration of activated charcoal in the home, especially in cases of acute poisoning in children.

Charcoal is contraindicated in individuals with unprotected airways and decreased levels of consciousness if not intubated; after ingestion of acids or alkalis; cases in which the risk or severity of aspiration is increased; or after isolated ingestion of lithium, iron, heavy metals, or ethanol.


Avoid use. Information regarding safety and efficacy in pregnancy and lactation is lacking.


None well documented.

Adverse Reactions

Emesis is the most common adverse reaction. Use in poisoning is associated with a risk of aspiration and subsequent chemical pneumonitis. GI obstruction can develop in patients receiving repeated doses.

Caution should be used in those at risk of gastric hemorrhage or perforation, or in those who have ingested a substance that increases the risk of sudden onset of seizures or sudden decreases in mental status.


Minimal toxicity is associated with the use of charcoal in hemoperfusion.


Charcoal is produced by pyrolysis and high temperature oxidation of organic materials. Animal charcoal is obtained from items such as charred bones, meat, and blood. Activated charcoal is obtained from charred wood or vegetable matter and treated with various substances to increase its adsorptive power. Amorphous carbons (or charcoals) are taken from the incomplete combustion of natural gas, fats, oils, or resins.(Lapus 2007)


Charcoal has been used for medicinal purposes for thousands of years. Ancient Egyptian papyri document use of charcoal as early as 1500 BC for the adsorption of odor from rotting wounds. Hindu documents from 450 BC record the use of charcoal and sand filters for the purification of drinking water. Hippocrates and Pliny describe the use of charcoal to treat epilepsy, chlorosis, and anthrax.(Lapus 2007)

In 1773, the German-Swedish pharmaceutical chemist Carl Scheele recognized the specific adsorptive powers of charcoal with various gases. At a meeting of the French Academy of Sciences in 1831, a pharmacist ingested several times the lethal dose of strychnine with equal amounts of charcoal and survived. However, the Academy members were unimpressed by this demonstration, and charcoal continued to be used primarily for industrial purposes.(Lapus 2007)

In 1911, the first industrially activated charcoal was made in Austria. Shortly afterward, the use of toxic gases in World War I drove the mass production of activated charcoal suitable for respirators. However, it was not until 1963, after a review article was published in the Journal of Pediatrics, that activated charcoal became more widely accepted in the management of ingested toxins.(Lapus 2007)


The chemistry of charcoal is complex. Although the purest forms essentially consist of all carbon, the small amounts of impurities that remain following combustion of the source material have been difficult to characterize. Medicinal charcoals have been developed with a high surface area-to-weight ratio in order to maximize adsorption capacity. The adsorptive properties of charcoal can be increased by treatment with substances such as carbon dioxide, oxygen, air, steam, sulfuric acid, zinc chloride, or phosphoric acid (or combinations of these) at high temperatures (500 to 900°C). These materials help remove impurities and reduce the particle size of carbon, allowing more adsorption due to increased surface area. One milliliter of finely subdivided and activated medicinal charcoal has a total surface area of approximately 1,000 m2. Medicinal or activated charcoal is a fluffy, fine, black, odorless, and tasteless powder without gritty material. It is insoluble in water or other common solvents but may be suspended for a short time after vigorous shaking.(Gennaro 1995)

Uses and Pharmacology

Acute poisoning antidote

Activated charcoal has been used in the management of acute toxicity for almost a century. Its large surface area permits the adsorption of a variety of complex chemicals, thereby rendering toxic material unavailable for systemic absorption. In addition, charcoal may interrupt the enterohepatic circulation of compounds excreted into the bile. It is usually coadministered with a laxative, which may hasten the elimination of toxins from the GI tract, resulting in diarrhea and more rapid GI transit time.(Juurlink 2016)

The use of activated charcoal in the treatment of poisoning is associated with a risk of aspiration and subsequent chemical pneumonitis. Activated charcoal for this use should only be administered under medical supervision.

Charcoal products sold for dental/oral health or other purposes are not appropriate for use in the management of acute poisoning. The American Academy of Pediatrics does not recommend administration of activated charcoal in the home, especially in cases of acute poisoning in children.(AAP 2003)

Dental and oral health

Clinical data

A randomized controlled crossover trial in 25 healthy participants demonstrated significantly lower tooth wear (P=0.004) and plaque (P<0) when a toothbrush with charcoal-infused nylon bristles was used for toothbrushing for 6 weeks compared with regular nylon bristles. No significant difference in gingival index scores was observed between toothbrushes. Teeth were brushed with a fluoridated dentifrice for 2 minutes during each phase of the study.(Kini 2019)

In a noncomparative study in which 60 young adults used a charcoal dentrifice (toothpaste) twice a day for 8 weeks, a number of oral health markers improved. Compared to baseline, improvements were documented for dental plaque (36% lower), tooth sensitivity (91% lower), and pain on probing (97% lower) at month 3. Additionally, enamel remineralization assessments demonstrated improvement in resistance to acid (by 48% at month 2), and 33% of patients experienced whitening of up to 1 tone. The anticaries index remained unchanged.(Chirkova 2018)

Diarrhea/Intestinal microbiome protective effects

Clinical data

Limited studies evaluating the use of activated charcoal in irinotecan-induced diarrhea showed reduced severity of diarrhea, resulting in a parallel reduction in loperamide consumption.(Michael 2004, Sergio 2008)

A randomized, controlled, single-blind study investigated the effects of a proprietary charcoal product on antibiotic-induced gut dysbiosis in 44 healthy volunteers with a body mass index (BMI) of less than 30 kg/m2. Participants received a 5-day regimen of the fluoroquinolone antibiotic moxifloxacin (with or without activated charcoal) or control (activated charcoal alone or nonactive substitute [negative control]). Coadministration of the delayed-release activated charcoal product prevented intestinal dysbiosis and maintained the gut microbiome richness to within 98% of baseline, which was comparable to untreated controls. The protective effect on gut microbiome was maintained for up to 16 days after antibiotic discontinuation. The marked microbiome composition changes observed in the moxifloxacin group were not observed in the activated charcoal alone or negative control groups.(de Gunzburg 2018)


Animal data

In a study evaluating the effect of charcoal on induced atherosclerosis secondary to nephrectomy in rats, no effect on serum cholesterol or triglycerides was noted.(Yamamoto 2011)

Clinical data

Clinical studies from the 1970s and 1980s suggest that charcoal has an effect on dyslipidemia. Reductions in blood lipid levels have been observed in patients with uremia treated with charcoal hemoperfusion, and repeated oral doses of activated charcoal were effective in reducing blood lipid concentrations in patients with uremia(Friedman 1977) and diabetes.(Manis 1980) In a study of hypercholesterolemic patients given activated charcoal, total cholesterol and LDL cholesterol levels decreased. HDL cholesterol and the HDL to LDL ratio increased.(Kuusisto 1986) This study resulted in an increased interest in the use of oral charcoal for the reduction of blood lipid levels, but there is insufficient evidence to confirm the effect on lipid parameters or to determine an appropriate dose.

Face mask toxicity

Clinical data

Based on data collected from a study conducted in China, wearing face masks made from binchotan charcoal fibers for 20 minutes led to a significantly lower accumulation of toxic chemical residues (ie, phenoxyethanol, methylparabens) from the masks compared with bio-cellulase–, bamboo charcoal fiber–, and plant cellulose–based masks (P<0.05). A 20% increase in exposure amount was observed when consumers switched from the binchotan charcoal–based mask to the plant cellulose–based mask. A dramatic increase was also seen when masks were worn for longer than 20 minutes. Other factors that significantly affected toxic chemical exposure and accumulation included sex (lower for males; P<0.001), facial sebum content (increase in sebum reduced toxin exposure; P=0.006), and contact area of the mask on the face (less face contact reduced toxin exposure (P=0.022).(Zhou 2022)


Clinical data

Capsules of powdered medicinal charcoal are promoted for use in relieving the discomfort of abdominal gas and flatulence(Gennaro 1995); however, limited clinical studies have been conducted to support this concept, and 1 study in healthy volunteers and functional patients found no effect of charcoal on bloating, abdominal pain, number of flatus episodes, abdominal girth, or cumulative breath hydrogen excretion.(Di Stefano 2000)


Clinical data

The American College of Rheumatology guidelines on the management of gout (2012) state that evidence is lacking to support the use of charcoal for gout. The new guideline (2020) based on additional evidence regarding the management of gout no longer includes a statement regarding the use of charcoal.(Fitzgerald 2020, Khanna 2012)

Malignant hyperthermia

Clinical data

The Association of Anaesthetists of Great Britain and Ireland consensus guidelines for malignant hyperthermia (2020) recommend that activated charcoal filters be available at all UK hospital locations where general anesthesia is administered.(Hopkins 2021) The European Malignant Hyperthermia Group (EMHG) consensus guidelines on the perioperative management of malignant hyperthermia suspected or susceptible patients (2021) recommend that activated charcoal filters be placed on the inspiratory and expiratory limbs of the circle systems to reduce volatile anesthetic concentrations (strong recommendation; low-quality evidence).(Ruffert 2021)

Renal disease

Clinical data

Limited clinical studies report on adsorption of toxins by charcoal in patients with chronic kidney disease (CKD) and those on hemodialysis.(Liu 2018, Schulman 2006, Wang 2012) Charcoal tablets administered to stable patients on hemodialysis facilitated serum and fecal metabolomes approaching that of controls. Abnormal tricarboxylic acid cycle intermediates were partially reversed, and the oxidative stress biomarker N1-acetyl-5-methoxykynuramine decreased significantly; however, uremic toxins were not significantly different compared to baseline.(Liu 2018)

A systematic review of clinical trials that investigated interventions to attenuate vascular calcification progression in CKD identified only one very low–quality study in which oral activated charcoal was administered. In 50 patients with stage 3 or 4 CKD enrolled in a randomized, controlled, phase 2 study, activated charcoal administered for 2 years reduced vascular calcification better than calcium carbonate but not as well as lanthanum carbonate.(Xu 2022)

Wound healing

Clinical data

Limited studies suggest accelerated healing rates using activated charcoal dressings with or without silver.(Keiheul 2010, Verdú 2004) In a study of rectal application of activated charcoal, 35.7% of patients had complete healing of chronic anal fistulas after 8 weeks.(Zawadzki 2017)


Acute poisoning antidote: In the management of poisonings, contact a poison control center. The American Academy of Pediatrics does not recommend administration of activated charcoal in the home, especially in cases of acute poisoning in children.(AAP 2003)

Pregnancy / Lactation

Avoid use. Information regarding safety and efficacy in pregnancy and lactation is lacking.


Because activated charcoal can adsorb drugs in the GI tract, it should be taken 2 hours before or 1 hour after other medications.(Gennaro 1995)

The American Academy of Pediatrics and the American Association of Poison Control Centers recommend that ipecac syrup and charcoal not be stocked at home.(AAP 2003) Simultaneous administration of charcoal and the emetic ipecac should be avoided; charcoal may adsorb the ipecac and render it ineffective.

Acetylcysteine: Activated charcoal may decrease the serum concentration of acetylcysteine. Monitor therapy. This interaction is only expected to occur with orally administered acetylcysteine.(Ekins 1987)

Amlodipine: Activated charcoal may decrease the serum concentration of amlodipine. Monitor therapy.(Laine 1997, Tanaka 2007)

Atazanavir: Activated charcoal may decrease the serum concentration of atazanavir. Monitor therapy.(Tseng 2013)

Chloroquine: Activated charcoal may decrease the serum concentration of chloroquine. Monitor therapy.(Neuvonen 1992)

Ciprofloxacin (systemic): Activated charcoal may decrease the serum concentration of ciprofloxacin (systemic). No action needed. This interaction is only expected to occur with orally administered ciprofloxacin.(Torre 1988)

Fluoxetine: Activated charcoal may decrease serum concentrations of the active metabolite(s) of fluoxetine. Activated charcoal may decrease the serum concentration of fluoxetine. Monitor therapy.(Laine 1996)

Leflunomide: Activated charcoal may decrease serum concentrations of the active metabolite(s) of leflunomide. Consider therapy modification.(Arava April 2009, Hassikou 2008, Knab 2005, Koenig 2002, Kozer 2001, Ochi 2006, Otsuka 2008, Richards 2007, Savage 2006, Takeishi 2005, Toyokawa 2007)

Moxifloxacin (systemic): Activated charcoal may decrease the serum concentration of moxifloxacin (systemic). Monitor therapy. This interaction is likely of greater significance when moxifloxacin is administered orally.(Stass 2005)

Phenobarbital: Activated charcoal may decrease the serum concentration of phenobarbital. Monitor therapy. This interaction is likely of greater clinical significance with orally administered phenobarbital.(Tanaka 2004)

Propranolol: Activated charcoal may diminish the therapeutic effect of propranolol. Monitor therapy. This interaction is only expected to occur with orally administered propranolol.(Sood 1999)

Rifampin: Activated charcoal may decrease the absorption of rifampin. Monitor therapy. This interaction is only expected to occur with orally administered rifampin.(Orisakwe 1996)

Teriflunomide: Activated charcoal may decrease the serum concentration of teriflunomide. Consider therapy modification.(Arava April 2009, Aubagio September 2012)

Unithiol: Activated charcoal may diminish the therapeutic effect of unithiol. Avoid combination. This interaction is only applicable to orally administered unithiol.(Dimaval June 2020)

Valproate products: Activated charcoal may decrease the serum concentration of valproate products. No action needed. This interaction is only expected to occur with orally administered valproate products.(al-Shareef 1997)

Adverse Reactions

The oral use of charcoal has been associated with adverse reactions, including GI obstruction due to formation of briquettes, which has been observed in patients who received repeated doses.(Anderson 1987, Watson 1986)


There is limited toxicity data for the use of charcoal in over-the-counter preparations. Activated charcoal's main use is as an antidote in poisoning; this is considered a medicinal use and should only administered under medical supervision in an appropriate setting. The American Academy of Pediatrics does not recommend administration of activated charcoal in the home, especially in cases of acute poisoning in children.(AAP 2003)



This information relates to an herbal, vitamin, mineral or other dietary supplement. This product has not been reviewed by the FDA to determine whether it is safe or effective and is not subject to the quality standards and safety information collection standards that are applicable to most prescription drugs. This information should not be used to decide whether or not to take this product. This information does not endorse this product as safe, effective, or approved for treating any patient or health condition. This is only a brief summary of general information about this product. It does NOT include all information about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this product. This information is not specific medical advice and does not replace information you receive from your health care provider. You should talk with your health care provider for complete information about the risks and benefits of using this product.

This product may adversely interact with certain health and medical conditions, other prescription and over-the-counter drugs, foods, or other dietary supplements. This product may be unsafe when used before surgery or other medical procedures. It is important to fully inform your doctor about the herbal, vitamins, mineral or any other supplements you are taking before any kind of surgery or medical procedure. With the exception of certain products that are generally recognized as safe in normal quantities, including use of folic acid and prenatal vitamins during pregnancy, this product has not been sufficiently studied to determine whether it is safe to use during pregnancy or nursing or by persons younger than 2 years of age.

al-Shareef A, Buss DC, Shetty HG, Ali N, Routledge PA. The effects of repeated-dose activated charcoal on the pharmacokinetics of sodium valproate in healthy volunteers. Br J Clin Pharmacol. 1997;43(1):109-111. doi:10.1111/j.1365-2125.1997.tb00041.x9056061
American Academy of Pediatrics Committee on Injury, Violence, and Poison Prevention. American Academy of Pediatrics policy statement: poison treatment in the home. Pediatrics. 2003;112(5):1182-1185. doi:10.1542/peds.112.5.118214595067
Anderson IM, Ware C. Syrup of ipecacuanha. Br Med J. 1987;294:578.
Arava (leflunomide) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis U.S. LLC, April 2009.
Aubagio (teriflunomide) [prescribing information]. Cambridge, MA: Genzyme Corporation, September 2012.
Chirkova NV, Popova TA, Shelkovnikova SG. Clinical evaluation of the effectiveness and safety of Biomed White Complex/Charcoal dentifrice. Austin J Dentistry. 2018;5(6):1-3.
de Gunzburg J, Ghozlane A, Ducher A, et al. Protection of the human gut microbiome from antibiotics. J Infect Dis. 2018;217(4):628-636. doi:10.1093/infdis/jix60429186529
Dimaval (DMPS) Hartkapseln (unithiol) [summary of product characteristics]. Berlin, Germany: Haupt Pharma Wulfing GmbH; June 2020.
Di Stefano M, Strocchi A, Malservisi S, Veneto G, Ferrieri A, Corazza GR. Non-absorbable antibiotics for managing intestinal gas production and gas-related symptoms. Aliment Pharmacol Ther. 2000;14(8):1001-1008. doi:10.1046/j.1365-2036.2000.00808.x10930893
Ekins BR, Ford DC, Thompson MI, Bridges RR, Rollins DE, Jenkins RD. The effect of activated charcoal on N-acetylcysteine absorption in normal subjects. Am J Emerg Med. 1987;5(6):483-487. doi:10.1016/0735-6757(87)90166-53663288
FitzGerald JD, Dalbeth N, Mikuls T, et al. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Rheumatol [published correction appearing in Arthritis Rheumatol. 2021;73(3):413]. 2020;72(6):879-895. doi:10.1002/art.4124732390306
Friedman EA. Oral sorbents in uremia: charcoal-induced reduction in plasma lipids. Am J Med. 1977;62(4):541-542. doi:10.1016/0002-9343(77)90413-2851128
Gennaro AR, ed. Remington: The Science and Practice of Pharmacy. 19th ed. Easton, PA: Mack Printing Co; 1995.
Hassikou H, El Haouri M, Tabache F, et al. Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis. Joint Bone Spine. 2008;75(5):597-599. doi:10.1016/j.jbspin.2007.08.01318805724
Hopkins PM, Girard T, Dalay S, et al. Malignant hyperthermia 2020: Guideline from the Association of Anaesthetists. Anaesthesia. 2021;76(5):655-664. doi:10.1111/anae.1531733399225
Juurlink DN. Activated charcoal for acute overdose: a reappraisal. Br J Clin Pharmacol. 2016;81(3):482-487. doi:10.1111/bcp.1279326409027
Kerihuel JC. Effect of activated charcoal dressings on healing outcomes of chronic wounds. J Wound Care. 2010;19(5):208, 210-212, 214-215. doi:10.12968/jowc.2010.19.5.4804720505594
Khanna D, Khanna PP, Fitzgerald JD, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 2: therapy and antiinflammatory prophylaxis of acute gouty arthritis. Arthritis Care Res (Hoboken). 2012; 64(10):1447-1461. doi:10.1002/acr.2177323024029
Kini V, Yadav S, Rijhwani JA, Farooqui A, Joshi AA, Phad SG. Comparison of plaque removal and wear between charcoal infused bristle and nylon bristle toothbrushes: A randomized clinical crossover study. J Contemp Dent Pract. 2019;20(3):377-384.31204332
Knab J, Goos M, Dissemond J. Successful treatment of a leg ulcer occurring in a rheumatoid arthritis patient under leflunomide therapy. J Eur Acad Dermatol Venereol. 2005;19:243-246. doi:10.1111/j.1468-3083.2005.01118.x.15752303
Koenig AS, Abruzzo JL. Leflunomide induced fevers, thrombocytosis, and leukocytosis in a patient with relapsing polychondritis. J Rheumatol. 2002;29:192-194.11824960
Kozer E, Moretti ME, Koren G. Leflunomide: New antirheumatic drug. Effect on pregnancy outcomes. Can Fam Physician. 2001;47:721-722.11340750
Kuusisto P, Vapaatalo H, Manninen V, Huttunen JK, Neuvonen PJ. Effect of activated charcoal on hypercholesterolaemia. Lancet. 1986;2(8503):366-367. doi:10.1016/s0140-6736(86)90054-12874369
Laine K, Kivisto KT, Laakso I, Neuvonen PJ. Prevention of amlodipine absorption by activated charcoal: effect of delay in charcoal administration. Br J Clin Pharmacol. 1997;43(1):29-33. doi:10.1111/j.1365-2125.1997.tb00029.x9056049
Laine K, Kivisto KT, Pelttari S, Neuvonen PJ. The effect of activated charcoal on the absorption of fluoxetine, with special reference to delayed charcoal administration. Pharmacol Toxicol. 1996;79(5):270-273. doi:10.1111/j.1600-0773.1996.tb00272.x8936562
Lapus RM. Activated charcoal for pediatric poisonings: the universal antidote? Curr Opin Pediatr. 2007;19(2):216-222. doi:10.1097/MOP.0b013e32801da2a917496769
Liu S, Liang S, Liu H, et al. Metabolite profiling of feces and serum in hemodialysis patients and the effect of medicinal charcoal tablets. Kidney Blood Pressure Res. 2018;43(3):755-767. doi:10.1159/00048991229804117
Manis T, Deutsch J, Feinstein EI, Lum GY, Friedman EA. Charcoal sorbent-induced hypolipidemia in uremia and diabetes. Am J Clin Nutr. 1980;33(7):1485-1488. doi:10.1093/ajcn/33.7.14856967252
Michael M, Brittain M, Nagai J, et al. Phase II study of activated charcoal to prevent irinotecan-induced diarrhea. J Clin Oncol. 2004;22(21):4410-4417. doi:10.1200/JCO.2004.11.12515514383
Neuvonen PJ, Kivisto KT, Laine K, Pyykko K. Prevention of chloroquine absorption by activated charcoal. Hum Exp Toxicol. 1992;11(2):117-120. doi:10.1177/0960327192011002101349217
Ochi S, Harigai M, Mizoguchi F, et al. Leflunomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: Autopsy findings with a mosaic pattern of acute and organizing diffuse alveolar damage. Mod Rheumatol. 2006;16(5):316-320. doi:10.1007/s10165-006-0506-217039315
Orisakwe OE, Dioka CE, Okpogba AN, Orish CN, Ofoefule SI. Effect of activated charcoal on rifampicin absorption in man. Tokai J Exp Clin Med. 1996;21(1):51-54.9239805
Osterhoudt KC, Durbin D, Alpern ER, Henretig FM. Risk factors for emesis after therapeutic use of activated charcoal in acutely poisoned children. Pediatrics. 2004;113(4):806-810. doi:10.1542/peds.113.4.80615060231
Otsuka T, Koyama T, Ohtani R, et al. Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease. Mod Rheumatol. 2008;18(1):96-99. doi:10.1007/s10165-007-0014-z18161003
Richards BL, Spies J, McGill N, et al. Effect of leflunomide on the peripheral nerves in rheumatoid arthritis. Intern Med J. 2007;37(2):101-107. doi:10.1111/j.1445-5994.2007.01266.x17229252
Rüffert H, Bastian B, Bendixen D, et al; European Malignant Hyperthermia Group. Consensus guidelines on perioperative management of malignant hyperthermia suspected or susceptible patients from the European Malignant Hyperthermia Group. Br J Anaesth. 2021;126(1):120-130. doi:10.1016/j.bja.2020.09.02933131754
Savage RL, Highton J, Boyd IW, et al. Pneumonitis associated with leflunomide: A profile of New Zealand and Australian reports. Intern Med J. 2006;36(3):162-169. doi:10.1111/j.1445-5994.2006.01035.x16503951
Schulman G. A nexus of progression of chronic kidney disease: charcoal, tryptophan and profibrotic cytokines. Blood Purif. 2006;24(1):143-148. doi:10.1159/00008945116361855
Sergio GC, Félix GM, Luis JV. Activated charcoal to prevent irinotecan-induced diarrhea in children. Pediatr Blood Cancer. 2008;51(1):49-52. doi:10.1002/pbc.2149118253955
Sood BR, Bhan A, Chakrabarti A. A study on the haemodynamic interactions between activated charcoal and propranolol/atenolol in normal human subjects. Indian J Physiol Pharmacol. 1999;43(1):109-113.27093747
Stass H, Kubitza D, Moller JG, Delesen H. Influence of activated charcoal on the pharmacokinetics of moxifloxacin following intravenous and oral administration of a 400 mg single dose to healthy males. Br J Clin Pharmacol. 2005;59(5):536-541. doi:10.1111/j.1365-2125.2005.02357.x15842551
Takeishi M, Akiyama Y, Akiba H, et al. Leflunomide induced acute interstitial pneumonia. J Rheumatol. 2005;32:1160-1163.15940779
Tanaka C, Ohtani H, Tsujimoto M, et al. Effects of dosing interval on the pharmacokinetic interaction between oral small spherical activated charcoal and amlodipine in humans. J Clin Pharmacol. 2007;47(7):904-908. doi:10.1177/009127000730162217585118
Tanaka C, Yagi H, Sakamoto M, et al. Decreased phenobarbital absorption with charcoal administration for chronic renal failure. Ann Pharmacother. 2004;38(1):73-76. doi:10.1345/aph.1D24114742799
Torre D, Sampietro C, Quadrelli C, Bianchi W, Maggiolo F. Effects of orally administered activated charcoal on ciprofloxacin pharmacokinetics in healthy volunteers. Chemioterapia. 1988;7(6):382-386.3219749
Toyokawa Y, Kingetsu I, Yasuda C, et al. Pancytopenia, including macrocytic anemia, associated with leflunomide in a rheumatoid arthritis patient. Mod Rheumatol. 2007;17(5):436-440. doi:10.1007/s10165-007-0613-817929140
Tseng AL, la Porte C, Salit IE. Significant interaction between activated charcoal and antiretroviral therapy leading to subtherapeutic drug concentrations, virological breakthrough and the development of resistance. Antivir Ther. 2013;18(5):735-738. doi:10.3851/IMP268524071918
Verdú Soriano J, Rueda López J, Martínez Cuervo F, Soldevilla Agreda J. Effects of an activated charcoal silver dressing on chronic wounds with no clinical signs of infection. J Wound Care. 2004;13(10):419, 421-423. doi:10.12968/jowc.2004.13.10.2668515575569
Wang Z, Cui M, Tang L, et al. Oral activated charcoal suppresses hyperphosphataemia in haemodialysis patients. Nephrology (Carlton). 2012;17(7):616-620. doi:10.1111/j.1440-1797.2012.01626.x22697887
Watson WA, Cremer KF, Chapman JA. Gastrointestinal obstruction associated with multiple-dose activated charcoal. J Emerg Med. 1986;4(5):401-407. doi:10.1016/0736-4679(86)90219-23805698
Xu C, Smith ER, Tiong MK, Ruderman I, Toussaint ND. Interventions to attenuate vascular calcification progression in chronic kidney disease: A systematic review of clinical trials. J Am Soc Nephrol. 2022;33(5):1011-1032. doi:10.1681/ASN.202110132735232774
Yamamoto S, Zuo Y, Ma J, et al. Oral activated charcoal adsorbent (AST-120) ameliorates extent and instability of atherosclerosis accelerated by kidney disease in apolipoprotein E-deficient mice. Nephrol Dial Transplant. 2011;26(8):2491-2497. doi:10.1093/ndt/gfq75921245127
Zawadzki A, Johnson LB, Bohe M, Johansson C, Ekelund M, Nielsen OH. An open prospective study evaluating efficacy and safety of a new medical device for rectal application of activated carbon in the treatment of chronic, uncomplicated perianal fistulas. Int J Colorectal Dis. 2017;32(4):509-512. doi:10.1007/s00384-016-2726-z27878619
Zhou L, Chen J, Chen T, et al. Investigation of actual exposure to facial sheet mask preceding its risk assessment. Sci Rep. 2022;12(1):1215. doi:10.1038/s41598-022-05351-335075174

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.